ClinicalTrials.gg
CompletedNCT02600819Updated Nov 5, 2020Results posted

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

A Phase 3 interventional study of E/C/F/TAF and B/F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-05.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
295th of 638
55 · median 48
Started
2015
with 35 others
Phase 3
76 of 765
4 open now
Registered
423rd of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 295th largest by enrollment of the 638 interventional ones that give a count, is one of 36 that started in 2015, is one of 76 in phase 3, and was the 423rd registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in human immunodeficiency virus (HIV-1) infected adults with end-stage renal disease (ESRD) on chronic hemodialysis (HD).

03

Conditions studied

  • HIV-1 Infection

Keywords

  • End stage renal disease
  • Hemodialysis
  • Open-label
  • HIV-1 Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently on a stable antiretroviral regimen for ≥ 6 consecutive months
  • Plasma -1 ribonucleic acid (RNA) concentrations \< 50 copies/mL for ≥ 6 months preceding the screening visit and have HIV-1 RNA \< 50 copies/mL at screening
  • No documented history of HIV-1 resistance to elvitegravir (EVG), emtricitabine (FTC), lamivudine (3TC) or tenofovir (TFV) and no history of switching off EVG, FTC, 3TC or TFV due to concern for resistance
  • Cluster determinant 4 (CD4+) T cell count ≥ 200 cells/μL
  • ESRD with estimated (eGFR) \< 15 mL/min by formula for creatinine clearance
  • On chronic HD for ≥ 6 months prior to screening
  • Adequate hematologic function ( ≥ 1,000/mm\^3; ≥ 50,000/mm\^3; ≥ 8.5 g/dL)

Key Exclusion Criteria:

  • co-infection
  • Any clinical history, condition, or test result that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements
  • Administration of other agents (unless approved by Gilead Sciences). Participation in any other clinical trial, including observational trials, without prior approval from the sponsor is prohibited while participating in this trial.
  • History or presence of allergy or intolerance to the study drugs or their components
  • A new acquired immunodeficiency syndrome (AIDS)-defining condition (excluding and percentage criteria) diagnosed within the 30 days prior to screening, with the exception of oropharyngeal candidiasis
  • Received solid organ or bone marrow transplant

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF

    Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.

    Drug: E/C/F/TAF

  • Experimental
    Open-Label Rollover Extension B/F/TAF

    At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.

    Drug: B/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48

    Treatment-emergent Adverse Events (TEAE) were defined as AEs with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the E/C/F/TAF (GEN Phase) study drug or all AEs for participants still on E/C/F/TAF. It also includes the AEs that led to premature discontinuation of E/C/F/TAF study drug. Clinical events and clinically significant laboratory abnormalities were graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities. Adverse events were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening).

    Time frame: First Dose Date Up to Week 48

Secondary outcomes

  1. GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 96

    Treatment-emergent Adverse Events (TEAE) were defined as events that met 1 or both of the following criteria as any AEs with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the E/C/F/TAF (GEN Phase) study drug for participants who did not participate in the BVY OL extension phase or the day prior to the date of the first B/F/TAF study drug dose for participants who participated in the BVY OL extension phase. It also includes the AEs that led to premature discontinuation of E/C/F/TAF study drug. Clinical events and clinically significant laboratory abnormalities were graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities. Adverse events were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening).

    Time frame: First Dose Date Up to Week 96

  2. GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the FDA Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  3. GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  4. GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  5. Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG), Cobicistat (COBI), Emtricitabine (FTC), and Tenofovir (TFV)

    AUCtau is defined as area under the concentration versus time curve over the dosing interval (i.e., concentration of drug over time).

    Time frame: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4

  6. PK Parameter: AUClast of EVG, COBI, FTC, Tenofovir Alafenamide (TAF), and TFV

    AUClast is defined as the area under the concentration versus time curve from time zero to the last observable concentration.

    Time frame: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4

  7. PK Parameter: Cmax of EVG, COBI, FTC, TAF, and TFV

    Cmax is defined as the maximum concentration of drug.

    Time frame: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4

  8. PK Parameter: Ctau of EVG, COBI, FTC, and TFV

    Ctau is defined as the observed drug concentration at the end of the dosing interval. Ctau has been presented in lieu of Cmin (specified in the protocol) to align with other Gilead studies. This change has no impact on the PK analysis as Ctau and Cmin are equivalent for all analytes.

    Time frame: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4

  9. GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Failure (M = F) Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 were analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.

    Time frame: Week 96

  10. GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Excluded (M = E) Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 were analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

    Time frame: Week 96

  11. BVY OL Extension Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 were analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

    Time frame: Week 48 of the BVY OL Extension Phase

  12. GEN Phase: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 96

    Time frame: Baseline; Week 96

  13. BVY OL Extension Phase: Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48 of the BVY OL Extension Phase

  14. GEN Phase: Change From Baseline in CD4 Percentage at Week 96

    Time frame: Baseline; Week 96

  15. BVY OL Extension Phase: Change From Baseline in CD4 Percentage at Week 48

    Time frame: Baseline; Week 48 of the BVY OL Extension Phase

07

Results

Posted Oct 16, 2018

Participant flow

Participants were enrolled at study sites in Europe and the United States. The first participant was screened on 14 December 2015. The last study visit occurred on 15 October 2019.

GEN Phase
Participant flow — GEN Phase
MilestoneE/C/F/TAF (GEN Phase)E/C/F/TAF to B/F/TAF (BVY OL Extension Phase)
Started550
Completed390
Not completed160
Withdrew: Adverse event20
Withdrew: Death20
Withdrew: Investigator's discretion40
Withdrew: Non-compliance with study drug10
Withdrew: Withdrew consent50
Withdrew: Lost to follow-up20
BVY OL Extension Phase
Participant flow — BVY OL Extension Phase
MilestoneE/C/F/TAF (GEN Phase)E/C/F/TAF to B/F/TAF (BVY OL Extension Phase)
Started010
Completed010
Not completed00

Outcome measures

PrimaryGEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48

Treatment-emergent Adverse Events (TEAE) were defined as AEs with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the E/C/F/TAF (GEN Phase) study drug or all AEs for participants still on E/C/F/TAF. It also includes the AEs that led to premature discontinuation of E/C/F/TAF study drug. Clinical events and clinically significant laboratory abnormalities were graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities. Adverse events were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening).

Time frame:
First Dose Date Up to Week 48
Reported as:
Number · percentage of participants
GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48
percentage of participantsE/C/F/TAF (GEN Phase)
GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 4832.7
SecondaryGEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 96

Treatment-emergent Adverse Events (TEAE) were defined as events that met 1 or both of the following criteria as any AEs with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the E/C/F/TAF (GEN Phase) study drug for participants who did not participate in the BVY OL extension phase or the day prior to the date of the first B/F/TAF study drug dose for participants who participated in the BVY OL extension phase. It also includes the AEs that led to premature discontinuation of E/C/F/TAF study drug. Clinical events and clinically significant laboratory abnormalities were graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities. Adverse events were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening).

Time frame:
First Dose Date Up to Week 96
Reported as:
Number · percentage of participants
GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 96
percentage of participantsE/C/F/TAF (GEN Phase)
GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 9643.6
SecondaryGEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the FDA Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the FDA Snapshot Algorithm
percentage of participantsE/C/F/TAF (GEN Phase)
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the FDA Snapshot Algorithm87.3 (75.5 to 94.7)
SecondaryGEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Algorithm
percentage of participantsE/C/F/TAF (GEN Phase)
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Algorithm81.8 (69.1 to 90.9)
SecondaryGEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA Snapshot Algorithm
percentage of participantsE/C/F/TAF (GEN Phase)
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA Snapshot Algorithm54.5 (40.6 to 68.0)
SecondaryPharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG), Cobicistat (COBI), Emtricitabine (FTC), and Tenofovir (TFV)

AUCtau is defined as area under the concentration versus time curve over the dosing interval (i.e., concentration of drug over time).

Time frame:
0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG), Cobicistat (COBI), Emtricitabine (FTC), and Tenofovir (TFV)
h*ng/mLE/C/F/TAF (GEN Phase)
EVG14284.8 ± 7790.26
COBI10179.5 ± 6009.28
FTC62929.9 ± 30199.63
TFV8715.0 ± 3432.16
SecondaryPK Parameter: AUClast of EVG, COBI, FTC, Tenofovir Alafenamide (TAF), and TFV

AUClast is defined as the area under the concentration versus time curve from time zero to the last observable concentration.

Time frame:
0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4
Reported as:
Mean · h*ng/mL
PK Parameter: AUClast of EVG, COBI, FTC, Tenofovir Alafenamide (TAF), and TFV
h*ng/mLE/C/F/TAF (GEN Phase)
EVG12857.6 ± 7894.09
COBI9558.7 ± 5963.16
FTC59057.4 ± 31485.96
TAF231.9 ± 123.46
TFV7664.2 ± 3958.36
SecondaryPK Parameter: Cmax of EVG, COBI, FTC, TAF, and TFV

Cmax is defined as the maximum concentration of drug.

Time frame:
0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4
Reported as:
Mean · ng/mL
PK Parameter: Cmax of EVG, COBI, FTC, TAF, and TFV
ng/mLE/C/F/TAF (GEN Phase)
EVG1258.5 ± 689.57
COBI1370.4 ± 920.15
FTC4875.0 ± 1981.03
TAF246.3 ± 185.69
TFV442.8 ± 181.03
SecondaryPK Parameter: Ctau of EVG, COBI, FTC, and TFV

Ctau is defined as the observed drug concentration at the end of the dosing interval. Ctau has been presented in lieu of Cmin (specified in the protocol) to align with other Gilead studies. This change has no impact on the PK analysis as Ctau and Cmin are equivalent for all analytes.

Time frame:
0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4
Reported as:
Mean · ng/mL
PK Parameter: Ctau of EVG, COBI, FTC, and TFV
ng/mLE/C/F/TAF (GEN Phase)
EVG174.4 ± 104.36
COBI28.9 ± 34.06
FTC1277.3 ± 756.60
TFV264.8 ± 193.98
SecondaryGEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Failure (M = F) Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 were analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.

Time frame:
Week 96
Reported as:
Number · percentage of participants
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Failure (M = F) Approach
percentage of participantsE/C/F/TAF (GEN Phase)
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Failure (M = F) Approach61.8 (47.7 to 74.6)
SecondaryGEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Excluded (M = E) Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 were analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

Time frame:
Week 96
Reported as:
Number · percentage of participants
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Excluded (M = E) Approach
percentage of participantsE/C/F/TAF (GEN Phase)
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Excluded (M = E) Approach100.0 (89.7 to 100.0)
SecondaryBVY OL Extension Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 were analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.

Time frame:
Week 48 of the BVY OL Extension Phase
Reported as:
Number · percentage of participants
BVY OL Extension Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach
percentage of participantsE/C/F/TAF to B/F/TAF (BVY OL Extension Phase)
BVY OL Extension Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach100.0 (69.2 to 100.0)
SecondaryGEN Phase: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · cells/µL
GEN Phase: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 96
cells/µLE/C/F/TAF (GEN Phase)
GEN Phase: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 96-35 ± 218.3
SecondaryBVY OL Extension Phase: Change From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48 of the BVY OL Extension Phase
Reported as:
Mean · cells/µL
BVY OL Extension Phase: Change From Baseline in CD4+ Cell Count at Week 48
cells/µLE/C/F/TAF to B/F/TAF (BVY OL Extension Phase)
Baseline581 ± 146.8
Change from Baseline at Week 48-104 ± 120.8
SecondaryGEN Phase: Change From Baseline in CD4 Percentage at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · percentage of CD4 cells
GEN Phase: Change From Baseline in CD4 Percentage at Week 96
percentage of CD4 cellsE/C/F/TAF (GEN Phase)
GEN Phase: Change From Baseline in CD4 Percentage at Week 962.8 ± 6.37
SecondaryBVY OL Extension Phase: Change From Baseline in CD4 Percentage at Week 48
Time frame:
Baseline; Week 48 of the BVY OL Extension Phase
Reported as:
Mean · percentage of CD4 cells
BVY OL Extension Phase: Change From Baseline in CD4 Percentage at Week 48
percentage of CD4 cellsE/C/F/TAF to B/F/TAF (BVY OL Extension Phase)
Baseline31.9 ± 7.37
Change from Baseline at Week 481.7 ± 4.39

Adverse events

Collected over First dose date up to the last dose date [maximum: 114 Weeks (GEN Phase), 52 Weeks (BVY OL Extension Phase)] plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E/C/F/TAF (GEN Phase)3/55 (5.5%)36/55 (65.5%)41/55 (74.5%)
E/C/F/TAF to B/F/TAF (BVY OL Extension Phase)0/10 (0%)3/10 (30%)10/10 (100%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventE/C/F/TAF (GEN Phase)E/C/F/TAF to B/F/TAF (BVY OL Extension Phase)
PneumoniaInfections and infestations8/551/10
HyperkalaemiaMetabolism and nutrition disorders6/551/10
Acute myocardial infarctionCardiac disorders2/551/10
Angina pectorisCardiac disorders1/551/10
Cardiac failure congestiveCardiac disorders1/551/10
Abdominal wall haematomaGastrointestinal disorders0/551/10
Pneumonia respiratory syncytial viralInfections and infestations0/551/10
Tendon ruptureInjury, poisoning and procedural complications0/551/10
Vascular access site haemorrhageInjury, poisoning and procedural complications0/551/10
Cervical spinal stenosisMusculoskeletal and connective tissue disorders1/551/10
Most frequent other events
Showing 10 of 52
Most frequent other events
EventE/C/F/TAF (GEN Phase)E/C/F/TAF to B/F/TAF (BVY OL Extension Phase)
NauseaGastrointestinal disorders13/551/10
HypertensionVascular disorders2/552/10
CoughRespiratory, thoracic and mediastinal disorders9/551/10
HyperkalaemiaMetabolism and nutrition disorders8/551/10
Oedema peripheralGeneral disorders6/550/10
Pain in extremityMusculoskeletal and connective tissue disorders6/550/10
BradycardiaCardiac disorders0/551/10
Ear painEar and labyrinth disorders1/551/10
CataractEye disorders1/551/10
DiplopiaEye disorders0/551/10

Baseline characteristics

The GEN Safety Analysis Set included all participants who received at least 1 dose of GEN.

Age, Continuous
Age, Continuous(years)E/C/F/TAF (GEN Phase)
Mean48 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)E/C/F/TAF (GEN Phase)
Female13
Male42
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)E/C/F/TAF (GEN Phase)
Hispanic or Latino8
Not Hispanic or Latino47
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)E/C/F/TAF (GEN Phase)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American45
White10
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)E/C/F/TAF (GEN Phase)
United States46
France7
Austria1
Germany1
HIV-1 RNA Category
HIV-1 RNA Category(Participants)E/C/F/TAF (GEN Phase)
< 50 copies/mL54
≥ 50 copies/mL1
Cluster Determinant 4+ (CD4+) Cell Count
Cluster Determinant 4+ (CD4+) Cell Count(cells/µL)E/C/F/TAF (GEN Phase)
Mean545 ± 239.2
CD4+ Cell Count Categories
CD4+ Cell Count Categories(Participants)E/C/F/TAF (GEN Phase)
< 50 cells/µL0
>= 50 to < 200 cells/µL0
>= 200 to < 350 cells/µL12
>= 350 to < 500 cells/µL14
>= 500 cells/µL29

1 further baseline measures are reported on the registry.

08

Study locations

26 sites
  • Peter J Ruane MD Inc
    Los Angeles, California, United States
  • University of California Davis
    Sacramento, California, United States
  • Midway Immunology & Research Center, LLC
    Fort Pierce, Florida, United States
  • Infectious Disease Consultants, M.D., P.A. d/b/a Orlando Immunology Center
    Orlando, Florida, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida, United States
  • Medical College of Georgia
    Augusta, Georgia, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia, United States
  • Mercer University School of Medicine
    Macon, Georgia, United States
  • The Research Institute
    Springfield, Massachusetts, United States
  • Henry Ford Health System
    Detroit, Michigan, United States
  • Prime Health Care Services - St Michael's LLC d/b/a Saint Michael's Medical Center
    Newark, New Jersey, United States
  • University of North Carolina at Chapel Hill / UNC School of Medicine
    Chapel Hill, North Carolina, United States
  • Duke University
    Durham, North Carolina, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina, United States
  • University of Cincinnati Med Center
    Cincinnati, Ohio, United States
  • MetroHealth Medical Center IRB
    Cleveland, Ohio, United States
  • North Texas Infectious Diseases Consultants
    Dallas, Texas, United States
  • Trinity Health and Wellness Center
    Fort Worth, Texas, United States
  • Gordon E. Crofoot MD PA
    Houston, Texas, United States
  • Otto Wagner Spital
    Wien, Austria
  • Hopital Henri Mondor
    Creteil, France
  • CHU de Nice-l Archet
    NICE Cedex 03, France
  • Hopital Saint Louis
    Paris Cedex 10, France
  • Hopital Bichat-Claude Bernard
    Paris, France
  • Centre Hospitalier de Tourcoing
    Tourcoing Cedex, France
  • Klinikum rechts der Isar, TUM
    Munchen, Germany
09

References and documents

Publications

  • Eron JJ Jr, Lelievre JD, Kalayjian R, Slim J, Wurapa AK, Stephens JL, McDonald C, Cua E, Wilkin A, Schmied B, McKellar M, Cox S, Majeed SR, Jiang S, Cheng A, Das M, SenGupta D. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV. 2018 Dec 13:S2352-3018(18)30296-0. doi: 10.1016/S2352-3018(18)30296-0. Online ahead of print. PubMed 30555051 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Sep 2017, 21 months.

Results were first posted in Oct 2018, 1 year after primary completion.

Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 21 months is below that.

Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2015
First posted
Nov 9, 2015
StartActual
Dec 14, 2015
Primary completionActual
Sep 29, 2017
CompletionActual
Oct 15, 2019
Results first posted
Oct 16, 2018
Last update
Nov 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02600819
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 9, 2015
Start date
Dec 14, 2015
Primary completion
Sep 29, 2017
Completion
Oct 15, 2019
Results posted
Oct 16, 2018
Last update
Nov 5, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Bictegravir

Start the discussion